Key facts
- SK Plasma’s last known valuation is $1.5B.
- It has raised $280.7M; the latest was IPO ($291.9M) in Jun 2025.
- Notable investors include Korea Investment Partners, Hahn & Company, SK Discovery.
- Status: In IPO Registration.
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for SK Plasma
- ·The full record, as it builds
Funding rounds
No funding rounds for SK Plasma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SK Plasma
Developer of plasma-derived medicine intended to promote human health and protect the environment. The company offers a plasma fractionation business and offers plasma-derived products that are essential medicines to treat diseases that can be directly linked to human life, such as congenital immunodeficiency diseases and hemophilia, enabling doctors to create social value to protect the health of human lives.
- Sector
- Healthcare
- HQ
- Seongnam-si, South Korea
- Founded
- 1970
- Employees
- 122
- Website
- skplasma.com/
- Ownership
- In IPO Registration
SK Plasma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SK Plasma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SK Plasma in its N-PORT filings yet. We sweep new filings monthly.